Submit a Request Contact Us

Capabilities

Confidence and insight before you license.

Everything you need to evaluate, access, and explore real-world evidence, all in one connected platform.

Work With Us

Before you buy

Free

Transparency and validation before you commit to anything.

After you buy

Licensed

Tools to get the most out of the record once it is yours.

Powered by Trio Intelligence

AI-powered note search, expert clinical validation, and curated real-world data behind every step.

The products

Start free. Scale when you're ready.

  1. TRIO-01 Before you buy Free

    Feasibility Request

    Ask a question about any disease state, drug class, or cohort. Our clinical team checks it against the curated record and tells you what Trio can answer, before you license anything.

    • written answer
    • confirmed cohort size
    • clinical team review

    Submit a Request

  2. TRIO-02 Before you buy Free

    Data Preview

    See real counts and coverage from the actual data, not a marketing estimate. Completeness by variable, note availability, and geography for your specific population.

    • live counts
    • variable completeness
    • note availability

    Ask for a Preview

  3. TRIO-03 Before you buy Free

    Discovery

    Our workbench for building a cohort yourself. Add conditions, medications, and criteria, and watch patient counts update as you refine the definition.

    • self-serve cohort builder
    • live patient counts
    • no commitment

    Request Access

  4. TRIO-04 After you buy

    Datacube

    A curated, approved dataset licensed for your use case, delivered with a schema, a data dictionary, and release notes, with optional weekly, monthly, or quarterly refreshes.

    • schema + data dictionary
    • release notes
    • scheduled refreshes

    Scope a Datacube

  5. TRIO-05 After you buy

    Reports

    A written analysis of your question, produced by our clinical team: cohort definition, the variables extracted, the findings, and the note evidence behind them, in the same format as our published feasibility reports.

    • clinical team authored
    • note-level evidence
    • publication ready

    See Example Reports

  6. TRIO-06 After you buy

    Explorer

    An analytics workbench for working directly with your licensed data: cohort comparisons, journey views, and export, without moving the data into your own stack first.

    • cohort comparison
    • journey views
    • export

    See Explorer

  7. TRIO-07 After you buy

    Trio API

    Programmatic access to Trio data for your own tools and pipelines, with the same definitions and provenance as every other delivery.

    • REST access
    • versioned definitions
    • provenance on every row

    Talk to Our Team

  8. TRIO-08 After you buy Add-on

    Analytics

    Our clinical and biostatistics team takes licensed data the last mile into publication: conference posters, congress abstracts, and peer-reviewed manuscripts, prepared to the same curation standard as our published work. An add-on to a Datacube, not a separate data purchase.

    • conference posters
    • abstracts & oral presentations
    • peer-reviewed manuscripts

    Scope an Engagement

The marketplace

Compare EHR datasets before you commit to one

Coverage, care setting, and note availability differ by source, and those differences decide whether a feasibility study is answerable. Every dataset is described in the same terms so the comparison is honest.

  • ƛ

    Lambda

    Total patients
    71.8M unique patients
    Health systems
    35 contributing systems
    Academic vs. community
    28 academic medical centers 86% 6 community health systems 14%
    Clinical notes
    30.2M patients with notes 42%
    Geography
    All 50 states represented Top 5 California 16.5M Virginia 8.3M Massachusetts 5.6M Washington 4.3M New York 3.7M
    Download the Overview
  • Ω

    Omega

    Total patients
    92.1M unique patients
    Facilities
    11.7K across 31 data suppliers
    Hospital vs. community
    74% community & ambulatory care Hospital & medical center 26%
    Clinical notes
    58.8M patients with notes 64%
    Geography
    All 50 states represented Top 5 Illinois 8.5M New York 7.8M Ohio 7.1M North Carolina 5.7M Texas 4.8M
    Download the Overview
  • A

    Alpha

    Total patients
    88.1M unique patients
    Care encounters
    1.9B documented encounters
    Payer / eligibility
    33.6M patients with coverage Payer linked 38%
    Clinical notes
    Coming soon not yet available for this dataset
    Geography
    All 50 states represented Top 5 New York 10.6M Massachusetts 8.7M Illinois 8.0M Texas 7.8M Washington 6.9M
    Download the Overview

  • Allergy Partners

    Coming soon

Trio Discovery cohort builder on two tablets

Discovery · free access

Build your cohort. See the counts yourself.

Discovery is our free workbench: set criteria, add conditions, and medications, and watch live patient counts move as you refine. No license, no commitment.

Request Access See Example Studies

Where it lands

Built for the questions that stall programs

  • Clinical development

    Which patients would actually qualify for the shorter regimen?

    Answered with
    • treatment history
    • cirrhosis status
    • baseline viral load
    • regimen duration

    Published

    Curry MP, Tapper EB, Bacon B, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017;46(5):540–548.

    826 patients: 8 weeks matched 12 weeks at 95% SVR in those who qualified.

    Read the Full Paper

  • HEOR

    Does the outcome hold once real-world patients are the population?

    Answered with
    • prior treatment failure
    • confirmed response
    • baseline severity
    • care setting

    Published

    Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017;24(1):22–27.

    1,597 patients followed in practice, including those who had already failed therapy.

    Read the Full Paper

  • Commercial & post-approval

    Does a common comedication quietly undercut our therapy?

    Answered with
    • concomitant meds
    • dose level
    • time on therapy
    • outcome at 12 wks

    Published

    Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893–1899.

    Results supported label guidance: no more than low-dose PPI daily during therapy.

    Read the Full Paper

225+ peer-reviewed publications across disease areas, every one built on the same curation standard.

Explore Our Entire Resource Library

Bring us the question your current data can't answer.

Tell us the population and the variables you need. We will show you what Trio holds, how it was validated, and whether the answer is there, before you license anything.

Submit a Request